Keywords
Faricimab
Conbercept
Intravitreal injection
Efficacy
Safety
Submitted : 2026-01-13
Accepted : 2026-01-28
Published : 2026-02-12
Abstract
Objective: To compare the clinical efficacy and safety of intravitreal injection of faricimab and conbercept in the treatment of diabetic macular edema (DME). Methods: A total of 50 patients diagnosed with DME in our hospital from January 2023 to May 2025 were selected and randomly divided into an observation group and a control group, with 25 cases in each group, using a random number table method. The observation group received intravitreal injection of faricimab, while the control group received intravitreal injection of conbercept. Both groups adopted a loading phase plus maintenance phase treatment regimen. The best-corrected visual acuity (BCVA, expressed in logMAR) and central subfield thickness (CST) of the two groups were compared before treatment and at 1, 3, and 6 months after treatment, and the incidence of adverse events during treatment was recorded. Results: The logMAR BCVA in the observation group was lower than that in the control group at 3 and 6 months after treatment (both p < 0.05). The CST in the observation group was smaller than that in the control group at 1, 3, and 6 months after treatment (all p < 0.05). There was no statistically significant difference in the overall incidence of adverse events between the two groups (χ2 = 0.189, p = 0.663). Conclusion: Both intravitreal injections of faricimab and conbercept are effective in improving visual acuity and reducing macular edema in patients with DME, with good safety profiles. However, faricimab demonstrates superior efficacy in the medium to long term (3 and 6 months) compared to conbercept, making it more suitable for long-term treatment of patients with DME.
References
Feng L, Zheng X, Wang W, et al., 2025, Clinical Observation on the Efficacy of Huayu Xiaozhong Decoction Combined with Intravitreal Injection in the Treatment of Diabetic Macular Edema. Journal of Hebei Traditional Chinese Medicine and Pharmacology, 40(2): 18–22.
Tang H, Li M, Wang D, et al., 2024, Effects of Grid-Pattern Photocoagulation in the Macular Area Combined with Ranibizumab on Serum VEGF and IL-6 Levels in Patients with Diabetic Macular Edema. Journal of Hunan Normal University (Medical Sciences), 21(3): 51–54.
Huang W, Chen S, Li Y, 2025, Research on the Influence of Conbercept Combined with Laser Treatment for Diabetic Macular Edema on Retinal Microstructure and Factors Affecting Treatment Response. Journal of Translational Medicine, 14(12): 147–152.
Wei X, Hu K, Du Y, et al., 2023, Research Progress on the Treatment of Diabetic Macular Edema and Age-Related Macular Degeneration with the Novel Bispecific Monoclonal Antibody Faricimab. International Journal of Ophthalmology, 23(10): 1677–1682.
Shao Y, Wu J, Wang Y, 2025, Interpretation of the 2024 Edition of the American Academy of Ophthalmology Clinical Practice Guideline for Diabetic Retinopathy. Recent Advances in Ophthalmology, 45(9): 673–678.
Chen M, Liu P, Wang X, et al., 2024, Research Progress on the Pharmacological Treatment of Diabetic Retinopathy. Journal of Shanghai Jiao Tong University (Medical Science), 44(7): 822–829.
Zeng X, Ren M, Zhang Y, 2025, Analysis of the Efficacy of Intravitreal Injection of Ranibizumab Combined with Retinal Laser Photocoagulation in Patients with Ischemic CRVO Complicated with Macular Edema of Different Ages. Theory and Practice of Medicine, 38(23): 4031–4034.
Wu H, Zheng J, Yu Y, et al., 2024, Observation on the Efficacy of Intravitreal Injection of Conbercept Combined with Laser Photocoagulation in the Treatment of Diabetic Macular Edema. Medical Forum Magazine, 45(3): 301–306.
Lu Y, Zhu R, 2025, Short-Term Efficacy of Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration. Jiangsu Medical Journal, 51(11): 1150–1153 + 1076.
Fang Y, Shi W, Zhou X, et al., 2025, Study on the Efficacy of Faricimab in the Treatment of Refractory Wet Age-Related Macular Degeneration. Practical Geriatrics, 39(7): 674–680.